Kos Biotechnology Partners Raises $123 Million for Life Sciences Fund

With $123 million in total commitments, Kos Biotechnology Partners has finalized the third closing of its inaugural fund, marking the largest venture capital launch in Greek history. The firm, operating out of New York and Athens, aims to bridge the gap between American drug development expertise and European scientific talent.

The fund, which launched in December 2025, secured backing from a syndicate of institutional investors, led by the Hellenic Development Bank of Investments, alongside various global family offices. By operating as the first life sciences-dedicated investment vehicle in Greece, the firm targets a broad spectrum of development, ranging from initial company formation through Series C funding.

Co-founders Dr. Simos Simeonidis and Alex Tzoukas designed the firm to leverage the convergence of novel biology and data science. The investment mandate focuses on three primary areas: novel therapeutics for unmet medical needs, next-generation pharma services, and computational platforms designed to reduce clinical development risks. To support these portfolio companies, the firm utilizes an advisory network of Greek-diaspora industry leaders.

Operational momentum is already underway, with the firm having completed its first two investments. This includes leading a financing round for Epikast, a provider of tech-enabled pharma services, and a forthcoming stake in a San Francisco-based biotech company. With the addition of partner Nikos Kostaras, formerly the Greece country head at IQVIA, the firm plans to execute several more deals before the end of the year.